Enhanced antitumor effects of DC-activated CIKs to chemotherapy treatment in a single cohort of advanced non-small-cell lung cancer patients

Yang, Lili; Ren, Baozhu; Li, Hui; Yu, Jinpu; Cao, Shui; Hao, Xishan; Ren, Xiubao

doi:10.1007/s00262-012-1311-8

Cited by 81 publications

(75 citation statements)

References 23 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…1 Approximately 80% to 85% of lung malignancies are NSCLC, with a 5-y survival rate of only 15%. 2,3 Surgery is the most effective treatment for NSCLC. However, 60% to 70% of patients with NSCLC experience postoperative recurrence and metastasis, resulting in a poor prognosis.…”

Section: Introductionmentioning

confidence: 99%

“…A series of clinical studies have shown that adjuvant CIT, such as CIK cells and NK cells, can lead to promising antitumor effects on various cancers, [17][18][19][20][21] including lung cancer. 3,[22][23][24][25][26] Several reviews and meta-analysis reports have also demonstrated the safety and effectiveness of adjuvant CIT in clinics. [27][28][29][30] However, the patterns of CIT require thorough investigation in order to achieve optimal outcome and cost-effectiveness.…”

Section: Introductionmentioning

confidence: 99%

See 1 more Smart Citation

Adjuvant cellular immunotherapy in patients with resected primary non-small cell lung cancer

et al. 2015

View full text Add to dashboard Cite

Postoperative non-small cell lung cancer (NSCLC) patients require adjuvant therapy to improve their prognosis. In this study, we investigated the efficacy of a sequential combination of autologous cellular immunotherapy (CIT) and chemotherapy for postoperative NSCLC. This retrospective study included 120 postoperative NSCLC patients: 60 cases received only chemotherapy; 33 cases received chemotherapy and sequential CIT with cytokine-induced killer (CIK) cells; and 27 cases received chemotherapy and sequential CIT with alternate CIK and natural killer (NK) cells. Survival analysis showed significantly higher overall survival rates in the CIT group compared with the control group. Overall survival was higher in patients who received CIT with alternate CIK and NK cells than those who received treatment with only CIK cells. Multivariate analysis showed that adjuvant CIT was an independent prognostic factor for overall survival of patients with NSCLC. In subgroup analyses, adjuvant CIT significantly improved the overall survival of patients with less than 60 y old and positive lymph node. In conclusions, these data indicate that adjuvant CIT, especially with alternate application of CIK and NK cells, is an effective therapeutic approach to prolong survival of patients with NSCLC, particularly for patients 60 y old with positive lymph nodes.

show abstract

Section: Introductionmentioning

confidence: 99%

Section: Introductionmentioning

confidence: 99%

Adjuvant cellular immunotherapy in patients with resected primary non-small cell lung cancer

et al. 2015

View full text Add to dashboard Cite

show abstract

“…Several types of immune cells, such as lymphokine-activated killer cells (9), tumor-infiltrating lymphocytes (10) and anti-CD3 monoclonal antibody-induced killer cells (11) have shown efficacy in advanced cancers. Among these cells, cytokine-induced killer (CIK) cells have several advantages compared with traditional immune cells, such as proliferating rapidly in vitro, exhibiting intensified antitumor activity and a broader spectrum of targeted tumors, and being associated with less severe side effects, which qualifies them as one of the most promising treatments, particularly for patients with advanced cancer (6,(12)(13)(14)(15)(16)(17). It is noteworthy that the antitumor activity of CIK cells may be activated…”

Section: Introductionmentioning

confidence: 99%

Enhanced antitumor effects and improved immune status of dendritic cell and cytokine-induced killer cell infusion in advanced cancer patients

Chen

Yang

Song

et al. 2017

Molecular and Clinical Oncology

View full text Add to dashboard Cite

“…Multidisciplinary approaches are required to develop novel treatments for advanced NSCLC (7). One of these multidisciplinary approaches is immunotherapy (7,8), an important and effective method in cancer treatment, particularly for advanced-stage disease (9).…”

Section: Introductionmentioning

confidence: 99%

Dendritic cell vaccine and cytokine-induced killer cell therapy for the treatment of advanced non-small cell lung cancer

et al. 2016

View full text Add to dashboard Cite

Abstract. The present study aimed to evaluate the survival time, immune response and safety of a dendritic cell (DC) vaccine and cytokine-induced killer (CIK) cell therapy (DC-CIK) in advanced non-small cell lung cancer (NSCLC). The present retrospective study enrolled 507 patients with advanced NSCLC; 99 patients received DC-CIK [immunotherapy group (group I)] and 408 matched patients did not receive DC-CIK, and acted as the control [non-immunotherapy group (group NI)]. Delayed-type hypersensitivity (DTH), quality of life (QOL) and safety were analyzed in group I. The follow-up period for the two groups was 489.2±160.4 days. The overall survival (OS) time was calculated using the Kaplan-Meier method. DTH was observed in 59 out of 97 evaluated patients (60.8%) and 67 out of 98 evaluated patients (68.4%) possessed an improved QOL. Fever and a skin rash occurred in 36 out of 98 patients (36.7%) and 7 out of 98 patients (7.1%) in group I. DTH occurred more frequently in patients with squamous cell carcinoma compared with patients with adenocarcinoma (77.1 vs. 40.4%; P=0.0013). Radiotherapy was not associated with DC-CIK-induced DTH (72.7 vs. 79.6%; P=0.18), but chemotherapy significantly reduced the rate of DTH (18.2 vs. 79.6%; P=0.00). The OS time was significantly increased in group I compared with group NI (P=0.03).In conclusion, DC-CIK may induce an immune response against NSCLC, improve the QOL, and prolong the OS time of patients, without adverse effects. Therefore, the present study recommends DC-CIK for the treatment of patients with advanced NSCLC. IntroductionLung cancer is the leading cause of cancer-associated mortality and the most common cancer type worldwide (1). In total, ~80% of all lung cancer cases are non-small cell lung cancer (NSCLC) (2), for which surgery, chemotherapy and radiotherapy remain the standard treatments (3). The majority of patients with NSCLC are not recommended for surgery, since patients are often diagnosed at an advanced stage of disease (stage IIIb or IV). Patients that do undergo radical surgery may eventually develop locoregional recurrence or distant metastasis (4). Characterized by inexorable disease progression, advanced NSCLC usually has a high malignant potential. Its prognosis is poor and the clinical onset is extensive, despite treatment with chemotherapy and radiation (5). Systemic chemotherapy is the recommended first-line treatment for patients with advanced stage and metastatic NSCLC, but it is often considered ineffective or excessively toxic (6).Multidisciplinary approaches are required to develop novel treatments for advanced NSCLC (7). One of these multidisciplinary approaches is immunotherapy (7,8), an important and effective method in cancer treatment, particularly for advanced-stage disease (9). Immune cells, including cytokine-induced killer (CIK) cells and dendritic cells (DCs), aid in mounting an effective immune response against cancer cells and kill cancer cells, including residual cells (10-13). A combination of conventional methods, such as surgery...

show abstract

Enhanced antitumor effects of DC-activated CIKs to chemotherapy treatment in a single cohort of advanced non-small-cell lung cancer patients

Cited by 81 publications

References 23 publications

Adjuvant cellular immunotherapy in patients with resected primary non-small cell lung cancer

Adjuvant cellular immunotherapy in patients with resected primary non-small cell lung cancer

Enhanced antitumor effects and improved immune status of dendritic cell and cytokine-induced killer cell infusion in advanced cancer patients

Dendritic cell vaccine and cytokine-induced killer cell therapy for the treatment of advanced non-small cell lung cancer

Contact Info

Product

Resources

About